Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Love it! Thanks for posting it.
You know this is normal procedure, right? You file your papers then serve them on the opposing parties. LOL.
Yeah, me too. DeNunzio and Moody do a great job of structuring and finding good companies without diluting shareholders. Not so sure I trust that to anyone else, even if Moody/Denunzio help them get the shell started.
ALLQ and CHSO might also be good picks. I am in WBBA, CPSL, FTRK and ALLQ.
Hmmm, what do you think about that Papalaka. Have you invested in one set up like this before?
Yeah, if there's no opposition to the custodianship, there's no need for a hearing, especially during covid times when they are trying to avoid unnecessary appearances.
All of the Moody/Denunzio custodianships I've invested in didn't name others in their custodianships, but AEMC and BMRK have other people designated. Does anyone know what that's about? Are they setting these up on behalf of other individuals?
Custodianship hearing has been continued to 8/18. All of the Moody/Denunzio custodianships I've invested in didn't name others in their custodianships, but this one and BMRK have other people designated. Does anyone know what that's about. Are they setting these up on behalf of other individuals?
Thank you! Very interesting potential here!
Can you please post a link to the article. I can't locate it. Thanks.
Yes, the variants are really ramping up now. They've played their games with Gilead long enough and we need some real therapeutics now. The majority of the covid task force have previous and current financial ties to Gilead, so it's not surprising that they gave their drug Remdesivir first crack at covid. I'm very happy that our trials have been head to head with Remdesivir, so when we come out on top, there will be no denying Aviptadil.
That's awesome Outcast. Can't wait till you can hand him the keys to his new ride!
The question was posed to long investors what they thought about Colachis and whether she's still working for Cytodyn. I gave my opinion. I don't care whether she is listed on the website or not. It's not important to me. More important is the progress Cytodyn is making.
This whole kerfuffle over Colachis reminds me of the fuss some of the posters made over Mullholland leaving. After all the slanderous conspiracy theories posted here, did you feel bad at all when you heard his wife died? Did it ever occur to the group that he was well past retirement age? I'm just wondering?
And as far as the CRO goes, everyone knows that the updates to the clinical.gov sites lag the news. Anyone that wants to can do some DD and learn about Cytodyn's new potential CRO. It won't be Amarex.
Exactly! Really, this is all just normal procedure. Motions to amend, extensions of time, etc. are pretty typical. Nothing at all unusual about the case so far.
I support current management. Whether or not Arian Colachis is still working for the company is just speculation at this point, and probably not that newsworthy as corporate counsel can change as needs change. However, the new transactional firm Sidley Austin is a very high caliber firm, well suited to a growing biotech company.
I like the progress Cytodyn is making to associate themselves with well respected CRO's, the new PR company and now Sidley Austin. I like Colachis as well and hope she's still working for CYDY on general corporate matters.
Has anyone seen a signed version of that order? It looks like the proposed one that HCMC's counsel would prepare with their extension request. It's not valid until it's signed by the judge. Still in wait and see mode.
Nice close CPSL! Anyone else hungry? This is going to be big. Can't wait for the reveal.
Good luck getting a court to rule on anything before the annual meeting. The 13D would be lucky to even get a case filed in that time. Plus, they'd have to report to the SEC first, and that takes time. Forget it, the 13D takeover is over.
The 13D group claims to be concerned shareholders just wishing the best for CYDY. Well, perhaps they should do the right thing and start getting behind this company, instead of getting in the way?
CYDY is making some great positive strides, Recknor is moving at lightning speed, new PR firm, new high caliber transactional attorneys. CYDY is showing they can grow into a larger biotech. Support CYDY management on their path forward and shareholder value will increase. Of course, this assumes that the 13D are still actual shareholders, and at this point, I'm not sure that's the case. Two of the nominators weren't shareholders at the time they recommended the slate of the 13D, so who knows. The CYDY train is leaving the station and Pourhassan is the engineer. It's time to get on board or get out.
Nice! Thanks bb
Corporate lawyers do not typically handle civil litigation. Colachis is not the attorney of record for Cytodyn for the Goodwin case. The attorney that appeared for them is Fred Burnside.
If you read the Pacer record, looks like some cases were consolidated. They were still working on who the lead Plaintiff was going to be. Once it's all sorted out, then Cytodyn would answer the complaint.
If HCMC files an Amended Complaint before the deadline then the case is not over.
A voluntary dismissal is exactly that, the Plaintiff decided against proceeding with the lawsuit, period. If there was a settlement, that would be reflected in the filed court documents. There isn't one.
WBBA
I'll make it easy for you, invest in ALL of the Moody/DeNunzio plays (WBBA, ALLQ, FTRK, CHSO, CPSL). Great track record of shareholder value. They don't reverse split.
This is getting very, very interesting. ;)
No, Trump was given the drug by Regeneron, an early onset covid mab. It's given via IV within the first few days of covid.
Thanks for the update Chris9220. I have all the Moody/Denunzio merger stocks right now, except for CHSO. I'll have to pick some up.
Not true. HCMC has an opportunity to amend their Complaint and the judge has provided them a roadmap to do it. That’s all this is. The case isn’t going anywhere.
I'm not sure where you are getting the "hanging on by a thread" idea. They are growing and investing in other drug companies, purchasing two other ones just this year. GEM is a major shareholder in both RLF and NeuroRX so they have a vested interest in them both succeeding.
The patent includes all derivatives of Aviptadil, which means that any formulation that gets cooked up is still their intellectual property and shared via license with NeuroRX per the agreement.
RLFTF Investor relations was asked about the patent and the profit sharing agreement and they provided this response:
Thank you for your inquiry.
Relief owns U.S. Patent No. 8,178,489, related Patents derived from U.S. Patent Application Serial No. 11/817,867 and foreign formulation patents, which are being utilized under the Collaboration agreement with NeuroRx. Under the collaboration agreement, all potential new IP obtained by either Relief or NeuroRx related to aviptadil is required to be cross-licensed between the parties.
The binding collaboration agreement between Relief Therapeutics and NeuroRx entered into in September 2020 remains in full force and effect. Relief believes that it is in compliance with the collaboration agreement and that there are no grounds for renegotiating the profit sharing arrangements contained in the collaboration agreement. According to the agreement, Relief is entitled to 50% of the net profits from the sales in the NeuroRx territory, which includes the U.S., Canada and Israel.
Regarding questions relating to Relief's funding of the U.S. COVID-19 inhaled trial being conducted by NeuroRx, Relief has always been willing and able to fund the inhaled trial, upon NeuroRx presenting a detailed budget containing appropriate line items and underlying amounts and upon NeuroRx answering reasonable questions that we have posed to them asking for more details about their proposed trial budget. This has not happened to date. Nevertheless, we would also like to point out that Relief has already funded substantial expenses associated with NeuroRx's U.S. inhaled trial.
Kind regards,
Relief Therapeutics
Thanks Vatkens
Is there an update you can share? Is this one a typical moody custodianship or did he apply on behalf of someone else like AEMC and BMRK? Thanks
Thanks for the great post MC67. You make an important point. RLF is much, much more than a covid play.
Aviptadil versus Remdesivir? It's no contest. Aviptadil will be saving lives and shortening hospital stays. Remdesivir, not so much.
"Findings In this cohort study of 2344 US veterans hospitalized with COVID-19, remdesivir therapy was not associated with improved 30-day survival but was associated with a significant increase in median time to hospital discharge."
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2781959?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=071521
Thanks for the update on the patent situation. That was very helpful. Glad to see they are still collaborating and all versions of Aviptadil fall under Relief’s patent.
I agree Mister Money. All small pre revenue biotechs have challenges. Most drugs go through many trials before full approval. The only thing different this time was everyone expected more guidance and support from the FDA due to the pandemic. We saw how they approved Remdesivir in record time with only weak data and expected that they would help bring other promising drugs forward. That didn't happen, at least not for the critical population. Fauci and Remdesivir still reign supreme. I'm so glad that the company pivoted to overseas. I support the current board and will continue to do so as progress is being made.
An attorney in fact is not an attorney at law. An attorney in fact is an agent who is authorized to act on behalf of another person but isn't necessarily authorized to practice law. An attorney at law is a lawyer who has been legally qualified to prosecute and defend actions before a court of law. Migliarese is authorized to sign this type of document. Arian is an attorney at law. It's a totally different thing.
Makes a lot of sense PennyWorld.
That is a concern for me as well. However, I'm hopeful that if the FDA approves and EUA, then Europe will likely follow, which should raise our price more too.